This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Investing Ideas For Flu Season

Business Section: Investing Ideas

While there is still no flu panacea of sorts, the morphing disease has kept things interesting for biotech and pharmaceutical companies in the vaccine business.

Quadrivalent solutions may see better profit margins in a limited market of about 130-150 million Americans (less than half) each year. For big firms, flu vaccines are a minor source of revenue. For example, The business brings in about $718 mil for Novartis, less than 2% of yearly revenue.

But small companies have taken the unpredictable into their hands, on the lookout for better, more stable solutions to influenza. Think of the vaccine shortage in 2004 or the 2009 “swine” flue pandemic. These are ongoing issues that don’t have reliable protective measures.



Major flu vaccine manufacturers:

1. AstraZeneca PLC ( AZN, Earnings, Analysts, Financials): Develops, and commercializes prescription medicines for cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory and inflammation diseases worldwide. Market cap at $57.66B, most recent closing price at $46.31.


2. GlaxoSmithKline plc ( GSK, Earnings, Analysts, Financials): Engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. Market cap at $105.01B, most recent closing price at $42.73.


3. Sanofi ( SNY, Earnings, Analysts, Financials): Engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. Market cap at $118.38B, most recent closing price at $44.66.


4. Novartis AG ( NVS, Earnings, Analysts, Financials): Engages in the research, development, manufacture, and marketing of healthcare products worldwide. Market cap at $164.35B, most recent closing price at $60.73.


Companies developing a universal vaccine:

5. Dynavax Technologies Corporation ( DVAX, Earnings, Analysts, Financials): Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. Market cap at $514.68M, most recent closing price at $2.88.


2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs